So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research

Viruses. 2022 Jan 12;14(1):135. doi: 10.3390/v14010135.

Abstract

HIV infection requires lifelong antiretroviral therapy (ART) to control disease progression. Although ART has greatly extended the life expectancy of persons living with HIV (PWH), PWH nonetheless suffer from an increase in AIDS-related and non-AIDS related comorbidities resulting from HIV pathogenesis. Thus, an HIV cure is imperative to improve the quality of life of PWH. In this review, we discuss the origins of various SIV strains utilized in cure and comorbidity research as well as their respective animal species used. We briefly detail the life cycle of HIV and describe the pathogenesis of HIV/SIV and the integral role of chronic immune activation and inflammation on disease progression and comorbidities, with comparisons between pathogenic infections and nonpathogenic infections that occur in natural hosts of SIVs. We further discuss the various HIV cure strategies being explored with an emphasis on immunological therapies and "shock and kill".

Keywords: HIV latency; cure; human immunodeficiency virus (HIV); latency reversing agents (LRAs); nonhuman primate models; pathogenesis; reactivation; simian immunodeficiency virus (SIV); strategies.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Anti-Retroviral Agents / therapeutic use
  • CD8-Positive T-Lymphocytes / immunology
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV Infections / transmission
  • HIV-1 / physiology*
  • Humans
  • Life Cycle Stages
  • Macaca mulatta
  • Quality of Life
  • Simian Acquired Immunodeficiency Syndrome / immunology*
  • Simian Acquired Immunodeficiency Syndrome / transmission
  • Simian Immunodeficiency Virus / immunology*
  • Simian Immunodeficiency Virus / physiology
  • Virus Latency

Substances

  • Anti-Retroviral Agents